E2F3PROSTATECANCER · E2F3 - a potential clinical marker for prostate cancer
6РП — Действия „Мария Кюри“
- Период
- 2004-10-01 → 2006-09-30
- Финансиране от ЕС
- 159 613 €
- Участници
- 1
- Схема
- EIF
Линиите свързват координатора с партньорите.
Накратко на български
Протеинът E2F3 се изследва като потенциален маркер за рак на простатата чрез анализ на тъкани от 1200 пациенти. Това помага за разбирането на механизмите на заболяването и идентифицирането на нови генетични показатели за диагностика.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
Prostate cancer is now the leading cause of cancer related deaths in most European countries. However, knowledge of the underlying mechanisms is still scarce. The overall aim of this project is to identify new oncogenes involved in prostate cancer and assess their potential as clinical markers. The focus will be the E2F3 transcription factor that has an established role in cell cycle progression and has recently been proposed as a candidate oncogene for bladder cancer. Initial studies indicate that 70% of prostate cancers over-express E2F3.We will combine tissue microarray (TMA) staining data from 1200 prostate cancer patients with clinical data, and statistically analyse the correlation. We will also test the hypothesis that down regulation of pBR is needed for upregulation of E2F3 to have an impact, by studies of the pBR levels in parallel with the E2F3 analysis on the TMAs. We will determine whether the upregulation is associated with increased copy number of the gene by flourescence in situ hybridisation ( FISH) onto TMAs and, finally, the biological role of E2F3 in the development of prostate cancer will be investigated by siRNA technology in prostate cancer cell lines that over-express E2F3.
Оригинален текст от CORDIS (на английски).
Участници
- INSTITUTE OF CANCER RESEARCH : ROYAL CANCER HOSPITAL · LONDONКоординаторОбединеното кралство
Връзки
Данни: CORDIS, © Европейски съюз